je.st
news
Tag: immunotherapy
Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet
2014-03-04 23:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Data Presented at the 2014 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237). The data were presented for the first time during a late-breaking oral session at the 2014 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in San Diego. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orRobert Consalvo, 908-423-6595orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
house
study
phase
Canada approves Merck grass allergy immunotherapy
2014-02-03 23:56:05| Biotech - Topix.net
Merck & Co. says it's won its first approval for its new immunotherapy tablet for grass allergies, from regulators in Canada.
Tags: canada
grass
allergy
approves
Merck Statement on FDA Advisory Committee Meeting for RAGWITEK (Short Ragweed Pollen Allergen Extract), an Investigational Sublingual Allergy Immunotherapy Tablet
2014-01-29 03:26:07| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today said it was pleased with the positive discussion of RAGWITEK (Short Ragweed Pollen Allergen Extract) at the Allergenic Products Advisory Committee meeting of the U.S. Food and Drug Administration (FDA). Language: English read more
Tags: short
statement
meeting
committee
Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma
2014-01-13 14:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Expects to Complete Application in First Half of 2014 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, said today it has started a rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application for MK-3475, the companys investigational anti-PD-1 immunotherapy, for patients with advanced melanoma who have been previously treated with ipilimumab. A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing basis. Language: English Contact: MerckMedia:Ian McConnell, 908-423-3046Claire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-500-1101Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
advanced
application
license
Merck Statement on FDA Advisory Committee for GRASTEK (Timothy Grass Pollen Allergen Extract), Mercks Investigational Sublingual Allergy Immunotherapy Tablet
2013-12-13 01:17:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued the following statement after the conclusion of the Allergenic Products Advisory Committee of the U.S. Food and Drug Administration (FDA) meeting to discuss GRASTEK (Timothy grass pollen allergen extract). Language: English Contact: MerckMedia:Pamela Eisele, 908-423-5042orRobert Consalvo, 908-423-6595orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: statement
committee
advisory
grass